Abstract
Determination of GABA concentrations in human cerebrospinal fluid can be used to assess GABA-ergic activity in the central nervous system. As CSF free GABA concentrations may vary with age, sex, CSF fraction, and collection and storage conditions, careful attention to these factors are necessary to allow interpretation of results. Longitudinal studies to investigate the influence of pharmacological agents on CSF GABA have proven especially useful to define clinical biochemical activity and have been utilized to attribute the anti-epileptic action of vigabatrin, a selective inhibitor of GABA-transaminase, to its effects on brain GABA metabolism.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Roberts, E., and Frankel, S. 1950. Gama-aminobutyric acid in brain: Its formation from glutamic acid. J. Biol. Chem. 187:55–63.
Udenfriend, S. 1950. Identification of gamma-aminobutyric acid in brain by the isotope derivative method. J. Biol. Chem. 187:65–69.
Enna, S.J., Wood, J.H., and Snyder, S.H. 1977. Gamma-aminobutyric acid (GABA) in human cerebrospinal fluid: Radioreceptor assay. J. Neurochem. 28:1121–1124.
Bohlen, P., Schechter, P.J., van Damme, W., Coquillat, G., Dosch, J.-C., and Koch-Weser, J. 1978. Automated assay of gamma-aminobutyric acid in human cerebrospinal fluid. Clin. Chem. 24:256–260.
Hare, T.A., and Manyam, N.V.B. 1980. Rapid and sensitive ion-exchange fluorometric measurement of gamma-aminobutyric acid in physiological fluids. Anal. Biochem. 101:349–355.
Huizinga, J.D., Teelken, A.W., Muskiet, F.A.J., Jeuring, H.J., and Wolthers, B.G. 1978. Gamma-aminobutyric acid determination in human cerebrospinal fluid by mass-fragmentography. J. Neurochem. 30:911–913.
Achar, V.S., Welch, K.M.A., Chabi, E., Bartosh, K., and Meyer, J.S. 1976. Cerebrospinal fluid gamma-aminobutyric acid in neurological disease. Neurology 26:777–780.
Hare, T.A., Bala Manyam, N.V., and Glaeser, B.S. 1980. Evaluation of cerebrospinal fluid gamma-aminobutyric acid content in neurological and psychiatric disorders. Pages 171–187,in Wood, J.H. (ed.), Neurobiology of Cerebrospinal Fluid, Vol. 1, Plenum Press, New York.
Glaeser, B.S., Vogel, W.H., Oleweiler, D.B., and Hare, T.A. 1975. GABA levels in cerebrospinal fluid of patients with Huntington's chorea: A preliminary report. Biochem. Med. 12:380–385.
Hare, T.A., Wood, J.H., Ballenger, J.C., and Post, R.M. 1979. Gamma-aminobutyric acid in human cerebrospinal fluid: Normal values. The Lancet II:534–535.
Ben-Menachem, E., Persson, L., Schechter, P.J., Haegele, K.D., Huebert, N., and Hardenberg, J. 1989. Cerebrospinal fluid parameters in healthy volunteers during serial lumbar punctures. J. Neurochem. 52:632–635.
Grove, J., Palfreyman, M.G., and Schechter, P.J. 1983. Cerebrospinal fluid GABA as an index of brain GABA activity. Clin. Neuropharmacol. 6:223–229.
Perry, T.L., Hansen, S., Wall, R.A., and Gauthier, S.G. 1982. Human CSF GABA concentrations: Revised downward for controls, but not decreased in Huntington's chorea. J. Neurochem. 38:766–773.
McCarthy, B.W., Gomes, U.R., Neethling, A.C., Shanley, B.C., Taljaard, J.J.F., Potgieter, L., and Roux, J.T. 1981. Gamma-aminobutyric acid concentration in cerebrospinal fluid in schizophrenia. J. Neurochem. 36:1406–1408.
Enna, S.J., Stern, L.Z., Wastek, G.J., and Yamamura, H.I. 1977. Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. Arch. Neurol. 34:683–685.
Airaksinen, E.M., and Leino, E. 1982. Decrease of GABA in the cerebrospinal fluid of patients with progressive myoclonus epilepsy and its correlation with the decrease of 5HIAA and HVA. Acta. Neurol. Scand. 66:666–672.
Kuroda, H. 1983. Gamma-aminobutyric acid (GABA) in cerebrospinal fluid. Acta. Med. Okayama 37:167–177.
Norman, E.J., Wee, E.L., Berry, H.K., and Zimmerman, E.F. 1985. Rapid gas chromatographic-mass spectrometric quantitation of gamma-aminobutyric acid in biological specimens. J. Chromatog. 337:21–27.
Grossman, M.H., Hare, T.A., Manyam, N.V.B., Glaeser, B.S., and Wood, J.H. 1980. Stability of GABA levels in CSF under various conditions of storage. Brain Res. 182:99–106.
Grove, J., Schechter, P.J., Tell, G., Rumbach, L., Marescaux, C., Warter, J.-M., and Koch-Weser, J. 1982. Artifactual increases in the concentration of free GABA in samples of human cerebrospinal fluid are due to degradation of homocarnosine. J. Neurochem. 39:1061–1065.
Grove, J., Schechter, P.J., Tell, G., Koch-Weser, J., Sjoerdsma, A., Warter, J.-M., Marescaux, C., and Rumbach, L. 1981. Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid). Life Sci. 28:2431–2439.
Perry, T.L., Hansen, S., Schier, G.M., and Halpern, B. 1977. Isolation and identification of gamma-aminobutyryl-cystathionine from human brain and CSF. J. Neurochem. 29:791–795.
Perry, T.L., Hansen, S., and Kennedy, J. 1975. CSF amino acids and plasma-CSF amino acid ratios in adults. J. Neurochem. 24:587–589.
Fussi, F., Savoldi, F., and Curti, M. 1987. Identification of N-carboxyethyl gamma-aminobutyric acid in bovine brain and human cerebrospinal fluid. Neurosci. Lett. 77:308–310.
Haegele, K.D., Schwartz, J.-J., Schoun, J., Schmitt, A.H., and Schechter, P.J. 1987. 2-Pyrrolidinone in human cerebrospinal fluid: A major constituent of total gamma-aminobutyric acid. J. Neurochem. 49:1402–1406.
Bohlen, P., Huot, S., and Palfreyman, M.G. 1979. The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res. 167:297–305.
Grove, J., Schechter, P.J., Hanke, N.F.J., de Smet, Y., Agid, Y., Tell, G., and Koch-Weser, J. 1982. Concentration gradients of free and total gamma-aminobutyric acid and homocarnosine in human CSF: Comparison of suboccipital and lumbar sampling. J. Neurochem. 39:1618–1622.
Manyam, N.V.B., Hare, T.A., Katz, L., and Glaeser, B.S. 1978. Huntington's disease. Cerebrospinal fluid GABA levels in at-risk individuals. Arch. Neurol. 35:728–730.
Uhlhaas, S., Lange, H., Wappenschmidt, J., and Olek, K. 1986. Free and conjugated CSF and plasma GABA in Huntington's chorea. Acta. Neurol. Scand. 74:261–265.
Kuroda, H., Ogawa, N., Yamawaki, Y., Nukina, I., Ofuji, T., Yamamoto, M., and Otsuki, S. 1982. Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases. J. Neurol. Neurosurg. Psychiat. 45:257–260.
Manyam, B.V. 1982. Low CSF gamma-aminobutyric acid levels in Parkinson's disease. Effect of levodopa and carbidopa. Arch. Neurol. 39:391–392.
Teychenne, P.F., Lake, C.R., and Ziegler, M.G. 1980. Cerebrospinal fluid studies in Parkinson's Disease. Pages 197–206, Vol. 1,in Wood, J.H. (ed.), Neurobiology of Cerebrospinal Fluid, Plenum Press, New York.
Bareggi, S.R., Franceschi, M., Bonini, L., Zecca, L., and Smirne, S. 1982. Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications?. Arch. Neurol. 39:709–712.
Ferraro, T.N., and Hare, T.A. 1985. Free and conjugated amino acids in human CSF: Influence of age and sex. Brain Res. 338:53–60.
Hare, T.A., Wood, J.H., Manyam, B.V., Gerner, R.H., Ballenger, J.C., and Post, R.M. 1982. Central nervous system gammaaminobutyric acid activity in man. Relationship to age and sex as reflected in CSF. Arch. Neurol. 39:247–249.
Lippert, B., Metcalf, B.W., Jung, M. J., and Casara, P. 1977. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur. J. Biochem. 74:441–445.
Metcalf, B.W., Lippert, B., and Casara, P. 1978. Enzyme-activated irreversible inhibition of transaminases. Pages 123–133,in Seiler, N., Jung, M.J., and Koch-Weser, J. (eds.), Enzyme-activated Irreversible Inhibitors, Elsevier/North Holland Press, Amsterdam.
Jung, M.J., Lippert, B., Metcalf, B.W., Bohlen, P., and Schechter, P.J. 1977. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: Effects on brain GABA metabolism in mice. J. Neurochem. 29:797–802.
Schechter, P.J., Trainer, Y., Jung, M.J., and Bohlen, P. 1977. Audiogenic seizure protection by elevated brain GABA concentration in mice: Effects of gamma-acetylenic GABA and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur. J. Pharmacol. 45:319–328.
Schechter, P.J., Hanke, N.F.J., Grove, J., Huebert, N., and Sjoerdsma, A. 1984. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology 34:182–186.
Ben-Menachem, E., Persson, L.I., Schechter, P.J., Haegele, K.D., Huebert, N., Hardenberg, J., Schechter, P.J., Haegele, K.D., Huebert, N., Hardenberg, J., Dahlgren, L., and Mumford, J.P. 1988. Effects of single doses of vigabatrin on CSF concentrations of GABA, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epil. Res. 2:96–101.
Schechter, P.J. 1986. Vigabatrin. Pages 265–275,in Meldrum, B.S. and Porter, R.J. (eds.), Current problems in epilepsy. IV. New Anticonvulsant Drugs, John Libbey and Co., London.
Ben-Menachem, E., Persson, L.I., Schechter, P.J., Haegele, K.D., Huebert, N., Hardenberg, J., Dahlgren, L., and Mumford, J.P. 1989. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br. J. Clin. Pharm. 27:79S-85S.
Tell, G., Bohlen, P., Schechter, P.J., Koch-Weser, J., Agid, Y., Bonnet, A.M., Coquillat, G., Chazot, G. and Fischer, C. 1981. Treatment of Huntington's disease with gamma-acetylenic GABA, an irreversible inhibitor of GABA-transaminase: Increased CSF GABA and homocarnosine without clinical amelioration. Neurology 31:207–211.
Manyam, B.V., Katz, L., Hare, T., Kaniefsky, K., and Trembley, R.D. 1981. Isoniazid-induced elevation of GABA levels and effects on chorea in Huntington's chorea. Ann. Neurol. 10:35–37.
Zimmer, R., Teelken, A.W., Cramer, H., Ruther, E., and Gundurewa, M. 1980. Biochemical investigations into the mode of action of Na-valproate and valproinic acid, respectively. Arzneimittelforschung 30:1213.
Neophytides, A.N., Suria, A., and Chase, T.N. 1978. Cerebrospinal fluid GABA in neurologic disease. Neurology 28:359.
Snoek, J.W., Van Weerden, T.W., Teelken, A.W., Van den Burg, W., and Lakke, J.P.W.F. 1987. Meige syndrome: Doubleblind crossover study of sodium valproate. J. Neurol. Neurosurg. Psychiat. 50:1522–1525.
Loscher, W., and Schmidt, D. 1987. Diazepam increases gamma-aminobutyric acid in human cerebrospinal fluid. J. Neurochem. 49:152–157.
Gattaz, W.F., Roberts, E., and Beckmann, H. 1986. Cerebrospinal fluid concentrations of free GABA in schizophrenia: No changes after haloperidol treatment. J. Neural. Transm. 66:69–73.
Author information
Authors and Affiliations
Additional information
Special issue dedicated to Dr. Sidney Udenfriend.
Rights and permissions
About this article
Cite this article
Schechter, P.J., Sjoerdsma, A. Clinical relevance of measuring GABA concentrations in cerebrospinal fluid. Neurochem Res 15, 419–423 (1990). https://doi.org/10.1007/BF00969927
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00969927